Prospective Analysis of Safety and Efficacy of Tenofovir Alafenamide Fumarate (TAF) in European Real-World Patients with Chronic Hepatitis B: A Single-Centre Real-Word Cohort Study

Overview

Journal Pathogens

Date 2024 Sep 28

PMID 39339010

Authors

Balazs Fulop

Janett Fischer

Magdalena Hahn

Albrecht Bohlig

Madlen Matz-Soja

Thomas Berg

Florian van Bommel

Affiliations

Soon will be listed here.

Abstract

Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir for the treatment of chronic hepatitis B (CHB) that has shown a favourable renal safety profile while offering suppression of HBV DNA similar to tenofovir disoproxil fumarate (TDF). We aimed to study changes in markers of HBV replication and renal function in a real-world setting in European patients. In our prospective single-arm, non-interventional observational study, HBeAg-positive and HBeAg-negative patients with chronic HBV mono-infection receiving TAF as their first or following line treatment were enrolled. HBV DNA, HBsAg, markers of bone metabolism, and renal function were determined at baseline and every consecutive 3 months. A total of 50 patients (70% male) were included. The mean duration of TAF treatment was 18 (3-36) months. In 20 patients with detectable HBV DNA at baseline, median serum levels of HBV DNA log changed from 2.33 (0.766-6.47) to 1.04 IU/mL at the end of observation and became undetectable in 11 patients. Median HBsAg log decreased from 3.37 (0.88-5.10) to 2.39 (1.52-4.19) IU/mL. During the entire observation period, the renal function parameters remained stable in patients with normal renal function and even in those with renal dysfunction. Mild adverse events were reported by 14 patients (28%). TAF was a safe and effective treatment, also in patients with decreased renal function.

References

Huynh T, Bui D, Zhou T, Hu K . Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years. World J Hepatol. 2024; 16(7):1009-1017. PMC: 11287611. DOI: 10.4254/wjh.v16.i7.1009. View

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

Lim Y, Seto W, Kurosaki M, Fung S, Kao J, Hou J . Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther. 2022; 55(8):921-943. PMC: 9304567. DOI: 10.1111/apt.16788. View

Nishikawa T, Matsui M, Onishi S, Ushiro K, Asai A, Kim S . Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Int J Mol Sci. 2024; 25(4). PMC: 10888772. DOI: 10.3390/ijms25042245. View

Chan H, Buti M, Lim Y, Agarwal K, Marcellin P, Brunetto M . Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. Am J Gastroenterol. 2023; 119(3):486-496. PMC: 10903997. DOI: 10.14309/ajg.0000000000002468. View

Buti M, Wong D, Gane E, Flisiak R, Manns M, Kaita K . Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019; 4(4):296-304. DOI: 10.1016/S2468-1253(19)30015-9. View

Agarwal K, Brunetto M, Seto W, Lim Y, Fung S, Marcellin P . 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018; 68(4):672-681. DOI: 10.1016/j.jhep.2017.11.039. View

Ghany M, Buti M, Lampertico P, Lee H . Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. J Hepatol. 2023; 79(5):1254-1269. DOI: 10.1016/j.jhep.2023.06.002. View

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

10.

Hall A, Hendry B, Nitsch D, Connolly J . Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011; 57(5):773-80. DOI: 10.1053/j.ajkd.2011.01.022. View

11.

Sax P, Wohl D, Yin M, Post F, DeJesus E, Saag M . Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987):2606-15. DOI: 10.1016/S0140-6736(15)60616-X. View

12.

Chan H, Fung S, Seto W, Chuang W, Chen C, Kim H . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):185-195. DOI: 10.1016/S2468-1253(16)30024-3. View

13.

Lai C, Shi H, Tsai C, Yang Y, Chiu S . Cost-Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model. Cancers (Basel). 2024; 16(4). PMC: 10887268. DOI: 10.3390/cancers16040813. View

14.

Tian F, Houle S, Alsabbagh M, Wong W . Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics. 2019; 38(2):181-192. DOI: 10.1007/s40273-019-00852-y. View

15.

Sano T, Amano K, Ide T, Kawaguchi T, Kuwahara R, Arinaga-Hino T . Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B. Biomed Rep. 2020; 14(1):12. PMC: 7678628. DOI: 10.3892/br.2020.1388. View

16.

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson I . Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2012; 381(9865):468-75. DOI: 10.1016/S0140-6736(12)61425-1. View

17.

Lim J, Choi W, Shim J, Lee D, Kim K, Lim Y . Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B. Liver Int. 2022; 42(7):1517-1527. DOI: 10.1111/liv.15261. View

18.

Buti M, Gane E, Seto W, Chan H, Chuang W, Stepanova T . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):196-206. DOI: 10.1016/S2468-1253(16)30107-8. View

19.

Charlton M, Alam A, Shukla A, Dashtseren B, Lesmana C, Duger D . An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020; 55(9):811-823. PMC: 7452871. DOI: 10.1007/s00535-020-01698-4. View

20.

Fernandez-Fernandez B, Montoya-Ferrer A, Sanz A, Sanchez-Nino M, Izquierdo M, Poveda J . Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011; 2011:354908. PMC: 3119412. DOI: 10.1155/2011/354908. View